Drug design, development and therapy · 2026
Is Rituximab Suitable for Patients with Idiopathic Membranous Nephropathy Who are Seronegative for Anti-PLA2R Antibody?
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Yang, Xie Xiaojie, Yuan Fan, Zeng Fang, Wang Yu, Zhang Ran, Yan Wenjun, Luo Kaiping, Ren Daijin, Xu Gaosi
Аннотация
BACKGROUND: Rituximab (RTX) induces apoptosis in B cells expressing CD20, the efficacy in idiopathic membranous nephropathy (IMN) with seronegative anti-M-type phospholipase A2 receptor (PLA2R) antibody remains unclear.
METHODS: This multicenter retrospective study enrolled 111 adult patients with biopsy-proven, medium-to-high-risk IMN, whose serum anti-PLA2R antibodies test results were negative (SAb-). All patients received RTX and non-RTX (tacrolimus or cyclophosphamide) therapy. Subsequently, based on glomerular PLA2R antigen results, they divided into glomerular PLA2R positive (GAg+) and glomerular PLA2R negative (GAg-) groups. Compared the remission rate at 15 months between different treatment groups.
RESULTS: Of the 111 seronegative patients, 36 were assigned to the RTX group and 75 to the non-RTX group. Among the 76 GAg+ patients, 21 were in the RTX group and 45 in the non-RTX group. Kaplan-Meier analysis demonstrated that the complete remission rate was significantly higher in the non-RTX group than in the RTX groups at 15 months, both in total and SAb-/GAg+ cohort (P = 0.033, P = 0.034, respectively), but there was no statistically significant difference in overall remission (both P > 0.05). The non-RTX group exhibited significantly lower proteinuria and higher serum albumin levels than the RTX group at 3, 6, and 9 months after treatment. Of the 19 patients who did not achieve remission by the end of follow-up, seven (36.8%) experienced seroconversion. There were no significant differences in adverse events between two groups.
CONCLUSION: For seronegative anti-PLA2R antibodies patients, non-RTX immunosuppressive therapy might offer greater benefit for proteinuria remission compared to RTX in short-term, even if their glomeruli are positive for PLA2R antigen.
METHODS: This multicenter retrospective study enrolled 111 adult patients with biopsy-proven, medium-to-high-risk IMN, whose serum anti-PLA2R antibodies test results were negative (SAb-). All patients received RTX and non-RTX (tacrolimus or cyclophosphamide) therapy. Subsequently, based on glomerular PLA2R antigen results, they divided into glomerular PLA2R positive (GAg+) and glomerular PLA2R negative (GAg-) groups. Compared the remission rate at 15 months between different treatment groups.
RESULTS: Of the 111 seronegative patients, 36 were assigned to the RTX group and 75 to the non-RTX group. Among the 76 GAg+ patients, 21 were in the RTX group and 45 in the non-RTX group. Kaplan-Meier analysis demonstrated that the complete remission rate was significantly higher in the non-RTX group than in the RTX groups at 15 months, both in total and SAb-/GAg+ cohort (P = 0.033, P = 0.034, respectively), but there was no statistically significant difference in overall remission (both P > 0.05). The non-RTX group exhibited significantly lower proteinuria and higher serum albumin levels than the RTX group at 3, 6, and 9 months after treatment. Of the 19 patients who did not achieve remission by the end of follow-up, seven (36.8%) experienced seroconversion. There were no significant differences in adverse events between two groups.
CONCLUSION: For seronegative anti-PLA2R antibodies patients, non-RTX immunosuppressive therapy might offer greater benefit for proteinuria remission compared to RTX in short-term, even if their glomeruli are positive for PLA2R antigen.